Syndax Pharmaceuticals, Inc.
SNDX
$20.17
-$0.24-1.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 223.64% | 794.90% | 266.97% | 717.14% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 223.64% | 794.90% | 266.97% | 984.51% | -- |
| Cost of Revenue | 197.51% | 22.59% | -17.74% | 30.52% | -- |
| Gross Profit | 224.85% | 78.49% | 78.61% | 43.42% | -- |
| SG&A Expenses | -8.39% | 32.48% | 44.40% | 50.73% | 78.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.33% | 26.19% | 1.20% | 38.08% | 30.23% |
| Operating Income | 59.04% | 34.88% | 35.89% | 6.55% | -5.03% |
| Income Before Tax | 49.71% | 27.58% | 27.83% | -5.56% | -17.19% |
| Income Tax Expenses | -- | -33.33% | -- | -- | -- |
| Earnings from Continuing Operations | 49.71% | 27.77% | 27.83% | -5.56% | -17.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.71% | 27.77% | 27.83% | -5.56% | -17.19% |
| EBIT | 59.04% | 34.88% | 35.89% | 6.55% | -5.03% |
| EBITDA | 59.05% | 34.88% | 35.89% | 6.55% | -5.03% |
| EPS Basic | 50.89% | 29.07% | 28.82% | -4.26% | -15.89% |
| Normalized Basic EPS | 50.89% | 28.87% | 28.81% | -4.25% | -15.89% |
| EPS Diluted | 50.89% | 29.07% | 28.82% | -4.03% | -15.84% |
| Normalized Diluted EPS | 50.89% | 28.87% | 28.81% | -4.25% | -15.89% |
| Average Basic Shares Outstanding | 2.42% | 1.83% | 1.39% | 1.25% | 1.13% |
| Average Diluted Shares Outstanding | 2.42% | 1.83% | 1.39% | 1.25% | 1.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |